Unique Technology
Based on fully human synthetic phage display librairies
Best in class scientific expertise
International research team with over 100 years of combined expertise
Proprietary antibody
Outstanding human antibodies assets available for partnering and licensing
TECHNOLOGY
- Proprietary synthetic Ab library
- In vitro screening methods validated on:
- - Integral membrane proteins
- - Soluble proteins
- - Peptides
PIPELINE
- Innovative therapeutics antibodies with unique pH sensitive properties for oncology
- Full adaptability to various pharmaceutical development formats: ADC, TCE, CAR-T…
ABOUT US
Mabqi, founded upon best
in class technology from Inserm,
is a biotech company with an integrated
approach to develop human antibodies.
LATEST NEWS
Mabqi will be attending the FOB 2024
Mabqi will be attending the Festival of Biologics from October 15th to October 17th 2024 in Basel, Switzerland.
Mabqi will be attending at the Convention BIO US 2024
Mabqi will be attending the Convention BIO US innovation organization from June 3rd to June 6th at #SanDiego, #California #USA.
Mabqi contributed to the article « Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis » published in the journal Nature Communications on August 31, 2023.
Mabqi is proud to have contributed to the article "Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis" published in the journal Nature Communications on August 31, 2023.This study was conducted in collaboration with Laboratoires Servier. You can access the article by clicking on this link.